Title: Chief Executive Officer and Founder
Company: Transpire Bio Inc.
Location: Westin, Florida, United States
Xian-Ming Zeng, chief executive officer and founder at Transpire Bio Inc., has been recognized by Marquis Who’s Who Top Executives for dedication, achievements, and leadership in pharmaceuticals and biotechnology.
With nearly four decades of experience, Dr. Zeng has built a distinguished career in pharmaceuticals and biotechnology, specializing in inhalation medicines, drug development, drug delivery, and the pharmaceutical industry. He currently serves as the founder and chief executive officer at Transpire Bio Inc., a position he has held since 2022. In this role, his primary focus is developing effective and targeted drug delivery systems for lung diseases, with a core patient base in the U.S. and plans to expand into Europe, the U.K., and the Far East. His career includes serving as vice president at Smoore International in China from 2021 to 2022, executive vice president and head of global inhalation and complex injectables research and development at Lupin Pharmaceuticals from 2013 to 2021, vice president of global respiratory research and development at Teva Pharmaceutical Industries from 2006 to 2013, and led the pulmonary division at IVAX Pharmaceuticals in London from 1999 to 2005. Earlier in his career, he was a professor of pharmaceutics and director of research at the Medway School of Pharmacy, University of Kent, in the U.K. from 2005 to 2006, a lecturer in pharmaceutics at Xi’an Medical University in China from 1986 to 1992 and visiting professor at King’s College London.
Reflecting on his path, Dr. Zeng laid a solid educational foundation earning a bachelor’s degree from West China University of Medical Sciences in 1983, and a Master of Science in pharmaceutical science from the same institution in 1986. Following this, he earned his PhD in pharmaceutical sciences from King’s College London in 1997 and completed a fellowship with the Department of Pharmacy at King’s College London in 1999. In the early 1990s, he pursued research as a World Health Organization fellow at King’s College London. During this time, he collaborated with a professor specializing in occupational diseases, particularly focusing on silicosis, a lung disease prevalent among coal miners, also known as black lung disease. Together, they worked on developing therapeutic approaches to address this condition. His doctoral research at King’s College explored the delivery of dry powder aerosols for lung treatment, which laid the groundwork for his extensive career in inhalation therapy.
Dr. Zeng takes great pride in his pioneering research in aerosol technology. He began his academic career as a full professor at the University of Kent’s School of Pharmacy, where he was honored to be selected despite stiff competition. His industry experience includes serving as vice president and global head of risk factory product development for Teva Pharmaceuticals, followed by his role as global head of research and development of inhalation and complex injectables at Lupin Pharmaceuticals. In addition to his product work, he successfully established three research and development centers in South Florida. He attributes his success to his determination, the guidance he received from his educational advisor, and the support of his colleagues throughout his career. Looking ahead, he envisions Transpire Bio becoming a prominent company listed on NASDAQ, recognized as a global leader in developing respiratory medicines to address diseases with significant unmet medical needs.
For more information, please visit:
Contact Dr. Zeng:
